Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2019—Streck Retic-Chex Linearity for BC is now assayed for the Beckman Coulter UniCel DxH 900 analyzer. Retic-Chex Linearity for BC is designed to establish the reportable range and linearity of analyzers that report the reticulocyte parameter.
February 2019—Dragonfly Therapeutics has entered into a new agreement with Celgene to discover, develop, and commercialize immunotherapies for patients with solid and hematological cancers.
February 2019—The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
February 2019—London-based LGC announced the acquisition of SeraCare Life Sciences. SeraCare provides quality control materials for infectious disease testing through its Accurun reagents and next-generation sequencing reference materials through its Seraseq products for oncology, noninvasive prenatal testing, and inherited disease testing.
February 2019—Olaparib (Lynparza, AstraZeneca) has been approved by the FDA for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line, platinum-based chemotherapy.
January 2019—Menarini Silicon Biosystems announced the launch of its DEPArray FFPE SamplePrep Kit at the Association for Molecular Pathology’s annual meeting. The kit allows for the disaggregation and staining of formalin-fixed, paraffin-embedded tissue sections down to a single-cell suspension. The kit enables the detection, identification, and recovery of different cell populations by the DEPArray system based on specific immunofluorescent staining and DNA content. It has been tested using FFPE human tissue sections of primary and metastatic keratin-positive carcinomas in lung, breast, colon, pancreas, prostate, and ovarian tissues.
January 2019—SeraCare Life Sciences announced an exclusive partnership with AccuRef Diagnostics, a division of Applied StemCell, to market and sell AccuRef’s portfolio of CRISPR-engineered cell line reference materials alongside the Seraseq portfolio of NGS cancer products.
January 2019—Leica Biosystems has partnered with Ultivue to co-market Ultivue’s UltiMapper assays with Leica’s Bond Rx research staining platform.
January 2019—Qiagen launched its QIAscreen HPV PCR Test, a CE-marked in vitro molecular diagnostic test for the detection of 15 recognized high-risk genotypes of human papillomavirus. Validated sample types include cervical specimens collected in PreservCyt, Pathtezt, and Surepath collection medium, as well as self-collected vaginal brush specimens collected and shipped dry or in saline or self-collected cervico-vaginal lavage specimens.
January 2019—Quest Diagnostics and Oxford Immunotec announced that Quest has completed its acquisition of the U.S. laboratory services business of Oxford Immunotec; the T-Spot.TB tuberculosis and the Accutix tick-borne disease testing services are now part of Quest’s portfolio of infectious disease testing services.
